INVESTORS

PLURI’S 3D
CELL-BASED
TECHNOLOGY
INVESTORS & ESG

NASDAQ: PLUR

Change: -0.21%

Volume: $4,012

$3.69

TASE ISRAEL: PLUR

Change: -0.72%

Volume:₪11,443.00

₪12.41

Last Update: 2025-11-04 01:00

Last Update:2025-11-04 11:34

NASDAQ: PLUR

Change: -0.21%

Volume: $4,012

$3.69

Last Update: 2025-11-04 01:00

TASE ISRAEL: PLUR

Change: -0.72%

Volume:₪11,443.00

₪12.41

Last Update:2025-11-04 11:34

ABOUT PLURI

Pluri Inc. is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond.

Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production.

WHY INVEST IN PLURI?

  • Global presence over three continents, including the United States and Europe
  • Rich IP portfolio with over 250 patents globally and an in house GMP manufacturing facility
  • Two decades of experience in cell expansion technology 
  • Growing network of global partnerships

FROM THE PRESS

Please select listing to show.

IR CONTACT

Terms of Use

accessiblity

privacy policy

©2025 pluri inc

©2023 Pluri Inc.

©2023 Pluri Inc., its logo, brand, product, and process names appearing in this issue are the trademarks of Pluri™ Inc. or its affiliated companies. All other brand, product, and process names appearing are the trademarks of their respective holders. Reference to or use of a product, or process other than those of Pluri™ Inc. does not imply recommendation, approval, affiliation, or sponsorship of that product, or process by Pluri™ Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark, or other intellectual property right of Pluri™ Inc. or any third party, except as expressly granted herein.  All information herein is for general information only and is subject for change without notice.

NAME

Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.